Eagle Pharmaceuticals

290 articles about Eagle Pharmaceuticals

• Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results

  8/8/2019

  Eagle Pharmaceuticals, Inc. announced its financial results for the three- and six-months ended June 30, 2019

• Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer

  8/5/2019

  Eagle Pharmaceuticals, Inc. announced a clinical development plan to support the submission of a New Drug Application for the Company’s innovative fulvestrant formulation.

• Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019

  7/29/2019

  Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, before the market opens.

• Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference

  5/28/2019

  Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows:

• Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference

  5/15/2019

  Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference

• Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

  5/7/2019

  Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share

• Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure

  5/7/2019

  Statistically significant lower incidence of brain damage compared to control group, demonstrating neuroprotective properties of RYANODEX in treating nerve agent exposure

• Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019

  4/29/2019

  Eagle Pharmaceuticals, Inc. announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens.

• CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

  4/22/2019

  Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019

• Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH

  4/15/2019

  Eagle Pharmaceuticals, Inc. announced that it has expanded its existing BENDEKA™ licensing agreement with Teva Pharmaceuticals International GmbH.

• Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results

  2/28/2019

  Q4 2018 net income was $0.88 per basic and $0.86 per diluted share and adjusted non-GAAP net income was $1.23 per basic and $1.20 per diluted share

• Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

  2/19/2019

  Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February 28, 2019, before the market opens.

• Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference

• Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)

  11/27/2018

  Eagle to explore ARS indication to treat individuals exposed to high doses of radiation such as nuclear power plant leakage or nuclear weapons; additional research ongoing to evaluate hematopoietic syndrome in certain cancer patients undergoing radiation therapy

• Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

  11/27/2018

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows

• Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

  11/19/2018

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows

• Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

  11/1/2018

  Q3 2018 net income was $0.94 per basic and $0.91 per diluted share and adjusted non-GAAP net income was $1.22 per basic and $1.18 per diluted share

• Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization

  10/30/2018

  Q3 2018 preliminary EPS is expected to be $0.94 per basic and $0.91 per diluted share

• Eagle Pharmaceuticals Announces Results of Study for Fulvestrant

  10/30/2018

  Analysis of data shows fulvestrant did not meet bioequivalence criteria

• Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018

  10/25/2018

  Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 third quarter financial results on Thursday, November 1, 2018, before the market opens.